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Background: Human papillomavirus (HPV) infection has traditionally been regarded as a sexually transmitted
disease (STD), but recent evidence implicates that an infected mother can transmit HPV to her newborn during
pregnancy, at delivery, perinatal period or later. Given the lack of any studies on HPV-specific immune responses in
children, we conducted HPV16-specific cell-mediated immune (CMI) monitoring of the mother-child pairs with
known oral and genital HPV follow-up (FU) data since the delivery. In the Finnish Family HPV Study, 10 out of 331
mothers developed incident cervical intraepithelial neoplasia (CIN) during their 14-year FU. Our hypothesis
according to the common dogma is that there is no HPV16 specific immune response in offspring of the CIN
mother as she/he has not started the sexual life yet.
Methods: We used overlapping 30–35 mer peptides covering the entire HPV16 E2, E6 and E7 protein sequences.
Assays for lymphocyte proliferation capacity, cytokine production and HPV16-specific Foxp3 + CD25 + CD4+
regulatory T-cells were performed.
Results: HPV16-specific proliferative T-cell responses were broader in children than in their mothers. Nine of 10
children had responses against both E2 peptide pools compared to only 4 of the 10 mothers. Six of the 10 children
and only 2 mothers displayed reactivity to E6 and/or E7. The cytokine levels of IL-2 (p = 0.023) and IL-5 (p = 0.028)
induced by all peptide pools, were also higher among children than their mothers. The children of the mothers
with incident CIN3 had significantly higher IFN-γ (p = 0.032) and TNF-α (p = 0.008) levels than other children.
Conclusions: Our study is the first to show that also children could have HPV-specific immunity. These data indicate
that the children have circulating HPV16-specific memory T-cells which might have been induced by previous
HPV16 exposure or ongoing HPV 16 infection.
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Persistent high-risk (HR) human papillomavirus (HPV)
infection is the most important risk factor for cervical
cancer (CC). Of the HR-HPV genotypes, HPV16 is the
most prevalent, present in 50% of all CC cases worldwide
[1,2]. It has been estimated that over 80% of women will
encounter genital HPV infection during their life-time
[3] but only a minority of these infections will ever pro-
gress to malignancy [4,5]. Based on recent meta-analysis,
around 291 million women worldwide are carriers of HPV
DNA, of whom 32% are infected with HPV16 or HPV18,
or both [6].
HPV-induced immunity is crucial for clearance of the
infection. However, HPV is known to have several mech-
anisms to evade the host immune system, as recently
discussed [7-12]. HPV replication is linked with the dif-
ferentiation of keratinocytes in a way that inhibits virus
detection by the host. In productive HPV infections,
viral particles are released from the dying keratinocytes
on the epithelial surface. Thus, there is neither cytolysis
inducing inflammation nor pro-inflammatory cytokines
activating macrophages or Langerhans cells (LC) in in-
fected epithelia [8]. According to current concepts, there
is no blood-borne stage in the life cycle of HPV and the
viral early (E) proteins are expressed only at low levels in
the nucleus of an infected cell. Oncoproteins E5, E6 and
E7 of the HR-HPV can modulate antigen presentation
by impairing the assembly of peptide-MHC complexes,
and block the anti-viral responses at the stage of cell entry
and virus presentation, by modifying the production and
functions of cytokines such as interferons [7].
Until now, most research on HPV immunity has been
focused on cervical HPV infections in women. HPV im-
munity is based on circulating HPV-specific CD4+ T
helper (Th) and CD8+ cytotoxic T lymphocytes (CTLs)
of the adaptive, cell mediated immune (CMI) system
[12]. These cells can be targeted to the E and late (L)
HPV proteins and migrate to the site where the viral
proteins are presented [12]. In healthy subjects, circulating
CD4+ and CD8+ T cells specific for HPV16 E antigens are
frequently detected [13,14], while HPV-induced cervical
intraepithelial neoplasia (CIN) or CC are characterized
by weak HPV E antigen-specific T-cell immunity, and
these merely CD4+ T cells have an impaired capacity to
produce Th type 1 (Th1) and type 2 (Th2) cytokines
[7,12,13,15-17]. In contrast to effector cells, regulatory
T cells (Tregs) are known to suppress virus-specific im-
munity [18]. HPV16-specific Foxp3+ CD4+ regulatory
T-cells have been associated with immunosuppressive
responses as they are capable of inhibiting the proliferation
of naïve CD4+ T-cells and Th1-cells and their cytokine
production [17,19,20].
HPV infection has been traditionally considered as a
sexually transmitted disease (STD). However, recentmeta-analysis confirmed that newborns of the mothers
with genital HPV infection had 33% higher risk to acquire
HPV infection than those of HPV-negative mothers
[21,22]. Vertical transmission from an infected mother to
her newborn can occur during pregnancy via infected pla-
centa, cord blood, ascending cervical infection or through
an infected birth canal at delivery [23,24]. Horizontal HPV
transmission might occur for instance via breast-feeding,
from sibling via kissing or friends via digital contacts
[22,25]. Persistent oral HPV in newborn has been well
documented but with highly variable frequencies from 1%
up to 83% [26-29]. We have recently shown that 18% of
the oral samples of the newborns and 16% of the cervical
samples of mothers tested HPV DNA-positive. The HPV
genotype profile of the mother-newborn pairs was almost
identical at delivery but lost this similarity during the first
2 months [24].
The Finnish Family HPV study was designed in 1998
to elucidate the dynamics of HPV transmission between
the family members [30,31]. In the present study, we an-
alyzed the HPV16-specific CMI responses among the
women who developed an incident CIN. HPV16-specific
immunity was related to their known oral and genital
HPV DNA status and HPV serology during the FU. Of
special interest was to assess whether or not their children
have developed HPV16-specific CMI reactivity at the same
time point. Notable is that none of these children has been
HPV vaccinated or started his/her sexual debut.
Methods
Mothers and their children
The Finnish HPV Family Study is a longitudinal cohort
study conducted at the Department of Oral Pathology,
Institute of Dentistry, University of Turku and Department
of Obstetrics and Gynecology, Turku University Central
Hospital. The study plan was approved by the Research
Ethics Committee of Turku University Hospital (#3/1998
and 45/180/2010). Originally, 329 pregnant women at
their 3rd trimester pregnancy and all their newborns
(n = 331; included two twins) were enrolled in the study
between 1998 and 2001, as described previously [29-31].
During the FU until present, 12 women developed an inci-
dent CIN, as recently reported [32]. These women and
their children were recalled for blood sampling. Written
informed consent was obtained from 10 of these women,
with mean age of 37.0 years and 12.2 years of their
children, respectively. Three of the children were girls
and seven were boys. None of these children had had
any sexual contacts or received prophylactic HPV vac-
cination before or during study onset (Characteristics
of the mothers and their children are summarized in
Additional file 1: Table S1). As a negative control group
three healthy women who remained HPV negative during
FU were included with their children (in total two girls
Table 1 HPV16 peptides among the 8 peptide pools
HPV16 E2
Pool Peptide Amino acids Pool Peptide Amino acids
E2.1 E2-1 1-30 E2.2 E2.13 181-210
E2-2 16-45 E2.14 196-225
E2-3 31-60 E2.15 211-240
E2-4 46-75 E2.16 226-255
E2-5 61-90 E2.17 241-270
E2-6 76-105 E2.18 256-285
E2-7 91-120 E2.19 271-300
E2-8 106-135 E2.20 286-315
E2-9 121-150 E2.21 301-330
E2-10 136-165 E2.22 316-345
E2-11 151-180 E2.23 331-365
E2-12 166-195
HPV16 E6 HPV16 E7
Pool Peptide Amino acids Pool Peptide Amino acids
E6.1 E6.1 1-32 E7.1 E7.1 1-35
E6.2 19-50 E7.2 22-56
E6.2 E6.3 37-68 E7.2 E7.3 43-77





The original protein sequences were derived from NCBI Protein database:
http://www.ncbi.nlm.nih.gov/protein. Accession numbers: AAA46941.1 (HPV16 E2),
4927720 (HPV16 E6), and 739162 (HPV16 E7).
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same age as those in the study group. HPV detection
methods as well as the antibody screening against the
major capsid protein L1 of HPV 16 have been detailed in
previous reports [22,24,32,33].
The authors acknowledge the concept of the Minimal
Information About T cell Assays (MIATA) framework,
which was recently published [34,35]. Therefore, detailed
information is provided as structured in the proposed 5
modules by MIATA: the sample, the assay, the data acqui-
sition, the data analysis and the laboratory environment in
which the human T-cell assays were performed.
Blood samples
Venous blood samples were collected from mothers (74 mL)
and children (54 mL) in sodium-heparin collection tubes
and peripheral blood mononuclear cells (PBMCs) were
isolated within three hours by centrifugation over Ficoll-
Hypaque gradient (GE Healthcare Life Sciences, Uppsala,
Sweden) and washed with PBS. Viable and dead cells
were counted using trypan blue staining. For determining
the proliferative capacity of HPV16–specific T cells by
short–term lymphocyte stimulation test (LST), ~10×106
PBMCs were used and the remaining cells were frozen in
80% Fetal Bovine Serum (FBS, Biowest, EU quality) and
20% DMSO (Merck, Darmstadt, Germany) (10 million
PBMCs per mL per vial) using Nalgene™ Cryo 1°C Freez-
ing container, which ensures a −1°C/min rate of cooling,
at −70°C, and after 1–2 days stored the cryopreserved
PBMCs in liquid nitrogen until further use. The median
time from sample collection until beginning of LST or
cryopreservation was 3 hours. From 9 mL of blood col-
lected into clotting tube the serum was isolated by centri-
fugation for 7 minutes at 1000 g. Obtained autologous
serum was used for short-term T-cell proliferation assay
as described previously [36,37].
HPV16 peptides
Panels of overlapping 30–35 mer peptides with HPV16
E2, E6, and E7 protein sequences were synthesized by
solid phase peptide synthesis (SPPS) method with >95%
purity (ChinaPeptides Co. Shanghai, China), with a 14
(for 30-mer) or 15 (for 35-mer) amino acid (aa) overlap.
Two pools of E2 peptides (E2.1 and E2.2) consisted of
12 or 11 (30-mer) peptides, respectively. Four pools of
E6 and two pools of E7 peptides (E6.1-E6.4 and E7.1 and
E7.2) consisted of two 32-mer or 35-mer peptides, respect-
ively. The peptides are detailed in Table 1. Peptide quality
was tested by mass spectrum and high-performance liquid
chromatography (HPLC). Lyophilized peptides were
dissolved in distilled water or in water with 10% DMSO
for proper dissolution. Peptides were stored at −20°C
with the final concentration of 1 mg/mL. Eight peptide
pools were used to determine the proliferative capacityof HPV16-specific T-cells, for cytokine production analysis
and detection of the HPV16-specific Foxp3+ regulatory
T-cells. Memory response mix (MRM) stock solution
(50×), consisting of tetanus toxoid, 0.75 fL/mL (Statens
Serum Institut, Copenhagen, Denmark), Tuberculin PPD,
5 μg/mL (Statens Serum Institut), and Candida albicans,
0.015% (Greer Laboratories, Lenoir, USA) was used as a
positive control for the proliferation assays and cytokine
production capacity of the PBMCs [13].
Determination of the proliferative capacity of
HPV16–specific T cells by short–term lymphocyte
stimulation test (LST)
The freshly isolated PBMCs with a density of 1.5 × 105
cells per well were seeded into U-bottomed 96-wells mi-
crotiter plate (Nunc, Roskilde, Denmark). Eight replicative
wells were used for each peptide pool. The PBMCs were
cultured in IMDM (Gibco, Life Technologies, Belgium)
containing 10% autologous serum and the indicated
peptide pool at a final concentration of 5 μg/mL per
peptide. PBMCs cultured with MRM were used as a
positive control (10 μl/well of 4xMRM) and with no
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days of culturing the supernatants of all eight replicative
wells were collected and pooled for cytokine analysis. A
compensatory amount of IMDM supplied with 0.5 μCi
[3H]-Thymidine (PerkinElmer, Turku, Finland) per well
was added. After 18 hours of incubation, the cells were
harvested into Unifilter plates (PerkinElmer) using the
FilterMateTM Cell Harvester (PerkinElmer). Subsequently,
the filter plates were dried and counted on the 1450
MicroBeta + counter (PerkinElmer). The cut-off value for
counts per minute (CPM) values was determined by the
average plus 3 × SD of the eight medium-only control
wells. Stimulation index (SI) was calculated as the average
of tested eight wells divided by the average of the
medium-only control wells. The proliferative response
was defined positive if the CPM values of at least six of
the eight wells were above the cut-off value and if the SI
was ≥3 [13,14].
Analysis of cytokine production
The supernatants collected from LST at day 6 were ana-
lyzed using Cytometric Bead Array (CBA) human en-
hanced sensitivity flex set system (BD Biosciences, Temse,
Belgium) according to the manufacturer’s instructions. In
this array, the levels of IFN-γ, TNF-α, IL-2, IL-5, IL-10,
and IL-17A were determined. The detection limits for the
cytokines were based on standard curves complying with
the limit of 274 fg/mL described by the manufacturer. The
positive antigen-induced cytokine production was defined
as a cytokine concentration > 2× the concentration of the
medium-only control [38]. Cytokines were not analyzed in
the children of the negative control group.
Identification of HPV16 –specific CD4 + CD25 + Foxp3+
regulatory T cells
Frozen PBMCs were thawed and seeded into 24-wells
plate (1.0 × 106 cells/well). The cells were cultured in
IMDM containing 10% Human AB serum (Sigma-Aldrich,
San Louis, USA) and the indicated peptide pools (Table 1)
at a final concentration of 5 μg/mL per peptide. PBMCs
cultured with MRM were used as a positive control
(80 μl/well of 4xMRM) and without antigen (medium-
only) were used as a background control. After 7 days of
culturing, the cells were harvested, washed with 0.5% BSA
in PBS and stained first with surface markers CD25 (1:25)
(Anti-CD25 FITC, clone M-A251, BD Pharmingen, San
Diego, CA), CD4 (1:100) (Anti-CD4-APC, clone RPA-T4,
BD Pharmingen), CD8 (1:30) (Anti-CD8 PerCP-Cy5.5;
clone SK1, BD Pharmingen). Subsequently, the cells were
fixed and permeabilized using intra-nuclear staining buffer
set (FOXP3 Fix/Perm buffer set, Biolegend, San Diego,
CA) according to manufacturer’s instructions. Before
intracellular staining with Foxp3 (PE anti-human FOXP3,
Biolegend) or isotype control (PE Mouse IgG1, κ IsotypeCtrl, Biolegend), blocking was done with 2% FCS. All
staining procedures were done on ice. After staining, the
cells were washed, resuspended in PBS and measured by
the flow cytometer BD FACSCalibur (BD Bioscience).
Analysis was performed by using Flowing Software,
version 2.5.0 (Cell Imaging Core, Turku Centre for
Biotechnology, Turku, Finland). The fluorescent inten-
sity of MRM-stimulated and medium-only control cells
was used to set the gates for the other samples. An
antigen-induced alteration in the population percentage
was defined as a change of at least 2× the corresponding
percentage in the medium-only control [36,38]. HPV16 –
specific CD4 + CD25 + Foxp3+ regulatory T cells were not
determined in the children of the HPV negative control
group.
Statistical analysis
All statistical analyses were run using IBM SPSS® (IBM,
Inc., New York, USA) software package (IBM SPSS
Statistics for Windows, version 20.0.0.1). Frequency tables
were analysed using the χ2-test, with the likelihood ratio
or Fisher’s exact test for categorical variables. Differences
in the means of continuous variables were analysed using
non-parametric (Mann-Whitney or Kruskal-Wallis) tests
for two- and multiple independent samples, respectively.
Paired-samples test (Wilcoxon) was used to analyse the re-
sponse levels in mother-child pairs. All statistical tests
were two-sided and declared significant at p-value ≤0.05.
Laboratory environment
The laboratory of the Oral Pathology at the Institute of
Dentistry, Faculty of Medicine, University of Turku, Turku,
Finland, is a research laboratory where the T-cell assays are
performed according to SOPs, including the predefined
criteria for positive responses. All the methods needed for
the CMI studies were transferred from the laboratory of
van der Burg under his and Dr. Welter’s close guidance
and quality control.
Results
Woman with incident CIN and their children
Additional file 1: Table S1 summarizes the medical history
of the mothers’ cervical lesions, oral and genital HPV sta-
tus and HPV-specific serology, as well as the oral HPV
DNA status and HPV serology of their children, followed
since birth until present. Among the women with incident
CIN, five women had CIN3, three had CIN2 and two de-
veloped CIN1. Long-term persistence of HPV16 preceded
all incident CIN2 and CIN3 lesions. Five women (IDs 1A,
2A, 3A, 6A, and 8A) tested also occasionally HPV16-
positive in their oral mucosal samples (data not shown),
and seven women (IDs 1A, 2A, 3A, 4A, 6A, 7A and 10A)
had HPV16 antibodies detectable in sera at different time
points. Six children (IDs 2B, 3B, 5B, 6B, 8B, 10B) tested
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of whom two children were HPV16 positive (IDs 8B
and 10B).
Children have better HPV16-specific proliferative T-cell
response than their mothers
PBMCs of all ten mothers and children showed prolif-
erative response against MRM (Figure 1). The MRM
responses in mothers were stronger than in children,
although the range of SI was wide both in mothers
(30–271) and their children (12–164). HPV16-specific
proliferative T-cell response was found in 9 out of 10
mothers and in all the ten children at least to one of
the peptide pools of E2, E6 and E7 (Figure 1). Nine
mothers had reactivity to the peptide pool E2.1 (aa 1–195)
and four of them had reactivity also to the pool E2.2 (aa
181–365). Only two mothers had response to E6 peptides;
one to peptide pools E6.2 and E6.4 (ID2A) and the
other to peptide pool E6.3 (ID7A). No HPV16 E7-specific
response was found in any of the mothers.
One of the mothers had no response to any of the
peptide pools (ID10A). She had a persistent HPV16 in-
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Figure 1 Proliferative T-cell responses. Proliferative T-cell responses aga
children. (●) represents stimulation indexes of the mothers and (Δ) stimula
the same color. Only responses considered positive are shown. MRM =memdeveloped a CIN1 lesion with an HPV16/66 double in-
fection. She had HPV16 antibodies detectable only
once; one year after study entry, despite persisting
HPV16. In addition, she showed the lowest proliferative
T-cell response to the common recall antigens in the
MRM (Figure 2A) which might indicate an impaired over-
all CMI response. All but one (ID7A) of the mothers who
developed CIN2 or CIN3 displayed HPV16-specific prolif-
erative T-cell responses to E2.1 but did not respond to E6
and/or E7. This particular mother (ID7A) responded to
E6.3 (Figure 2A), confirming our previous data that
women with HSIL do not properly respond to the
oncoproteins E6 and E7 [17,39].
All children had HPV16-specific proliferative T-cell
response against the peptide pool E2.1, and 9/10 also
responded to the pool E2.2 (Figure 2A). An E6-specific
response to peptide pool E6.4 spanning the last aa
(109–158) was detected in five children, of whom two
had response also against the pool E6.2 (IDs 1B and 8B)
and two against pool E6.3 (IDs 1B and 5B). E7-specific
response to pool E7.2 spanning the second half of the
E7 protein (aa 43–98) was detected in three out of ten
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Figure 2 Results of LST, cytokine and Foxp3 assays among CIN1, CIN2 and CIN3 mothers and their children. A) HPV16 specific
lymphocyte stimulation test (LST) results. The mothers and their children are grouped according to the mothers CIN. Only positive responses are
marked with colored box and stimulation indexes are given in the boxes under the corresponding peptide pools. The blue color is used for the
mothers with CIN3 and their children, the red color for the mothers with CIN2 and their children and the green color represent mothers with
CIN1 and their children (the same color codes are used also in Figure 2B and 2C). Memory response mix (MRM) was used as a positive control
for LST assay. B) Cytokine assay results. Supernatants from the LST were analyzed for the presence of cytokines IFN-γ, TNF-α, IL-2, IL-5, IL-10, and
IL-17. One square in a box with 6 squares represents the production of the cytokine type as given in the index box lowest in the figure. Cytokines
found in those supernatants from wells with positive proliferative responses are marked with dark colors. Lighter colors are used when the
corresponding LST result was negative. C) Foxp3 assay results. The box, when marked is divided into two parts. The upper value presents the
percentages of (CD4 + CD25+) Foxp3–positive cells while the lower value presents the (CD4 + CD25+) Foxp3-negative cells after subtraction of
the medium-only control value. Only positive (upregulation) responses are shown. Upregulation of Foxp3+/− cells is defined as at least twice the
percentages of those in the medium-only control. Foxp3 = forkhead box P3, ND = not detectable.
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specific T-cell response, four of whom also responded
to E6 and/or E7. One child (ID8B) of HPV16+ CIN2
mother responded to multiple peptide pools of HPV16.
Also one child (ID10B) of the HPV16+ CIN1 mother
has response to E6.4 peptide pool. Interestingly, both
these children were the ones who harbored HPV16
infection in their oral mucosa at baseline.
Three healthy and HPV negative mothers also showed
positive LST responses to all peptide pools except for
E6.1 and E7.1 pools. Control group of mothers showed
responses to peptide pools E2.1 (mean of the SI 25,65,
range 22,07-28,57), E2.2 (mean of the SI 14,47, range
4,13-22,72), E6.2 (mean of the SI 4,07, range 0–4,07),
E6.3 (mean of the SI 10,68, range 0–10,68), E6.4 (mean
of the SI 13,98, range 4,74-23,21), E7.2 (mean of the SI
7,19, range 0–7,19) and MRM (mean of the SI 37,13,
range 22,07-48,35). The control group of mothers showed
slightly more E6 and E7 responses than the study group
and the control group of children showed fewer responsesto peptide pools E6 and E7 than the study group (data not
shown). One mother showed positive LST responses only
for E2.2 peptide pool when two others showed positive re-
sponses for both E2.1 and E2.2 peptide pools. In addition
to responses for peptide pools of E2, the one mother
showed responses also for peptide pools E6.2 and E6.4 and
the other mother showed responses also for E6.3, E6.4 and
E7.2 peptide pools. Control group of children showed re-
sponses only for peptide pools E2.1 (mean of the SI 11,56,
range 3,45-21,98), E2.2 (mean of the SI 7,20, range 4,24-
11,62), E6.4 (mean of the SI 4,48, range 0–4,48) and MRM
(mean of the SI 81,47, range 9,74-171,63). All responded
for peptide pools E2.1 and E2.2 and only one child also for
peptide pool E6.4 (data not shown).
Children of mothers with incident CIN3 have higher
HPV16-specific cytokine secretion by their T- cells than
those of their mothers
Figures 2B and 3 summarize the results of cytokines
produced by the PBMC in the LST of both the mothers
ID1 ID2 ID3 ID4 ID5 ID6 ID7 ID8 ID9 ID10
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Mothers Children Mothers Children Mothers Children
Mother / Child pairs: 
Figure 3 Cytokines accompanying the proliferative response of T cells in the LST. The cumulative amounts of the individual cytokine for all
peptide pools as determined by CBA are depicted. The mothers and their children are grouped according to the mothers CIN. Only cytokine
levels above detection limits are shown. The children of mothers having developed CIN3, showed significantly higher IFN-γ (p = 0.032) and TNF-α
(p = 0.008) levels than the other children. The cytokine levels of IL-2 (p = 0.023) and IL-5 (p = 0.028) induced by all peptide pools, were higher
among the children than their mothers. In the pair-wise comparison of the mother-child-pairs, the levels of IL-2 and IL-5 showed statistically
significant difference between the mother and child (p = 0.013 and p = 0.009, respectively). Control group of mothers showed highest cumulative
amounts cytokine levels for IFN-γ (mean 139,03, range 12,99-210,13), IL-17 (mean 60,00, range 3,39-101,04) and IL-10 (mean 40,29, range 7,30-83,24)
followed by IL-2 (mean 14,54, range 6,93-29,67), IL-5 (mean 13,65, range 1,65-29,13) and TNF-α (mean 2,88, range 0–6,41) (data not shown).
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CIN. Overall, IFN-γ, IL-17A and IL-2 were the most pre-
dominant cytokines followed by IL-10, IL-5 and TNF-α
in mothers, whereas all cytokines were found among the
children. IL-4 was rarely detected and therefore not
shown. HPV16–specific, Th1 cytokine (IFN-γ and TNF-α)
responses accompanying the proliferative T-cell responses
were found in 6/10 mothers and in 5/10 children. This
was frequently (in 5/6 mothers and in all children) accom-
panied by Th2 (IL-5 producing) T-cells. Mother ID3A was
the only mother who had no IFN-γ or IL-5 response forany of the peptide pools and showed a proliferative T-cell
response only against the pool E2.1 (Figures 2B and 3).
She developed an incident CIN2, HPV16 DNA being
detectable in her cervical and oral samples twice and
four times, respectively. In addition to HPV16, also
HPV genotypes 6, 31, 70, 82 (in cervical smear) and 66
(in oral sample) were detected. She also tested con-
stantly HPV6 seropositive.
HPV16 E2-specific IFN-γ producing T-cells to both E2.1
and E2.2 peptides were detected in 7 mothers (Figure 2B).
HPV16 E7.1 peptide specific IFN-γ producing T-cells were
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and E6.4 responses were found in three (IDs 6A, 9A,
10A), four (IDs 4A, 6A, 7A and 9A) and four (IDs 2A, 6A,
7A and 10A) mothers, respectively (Figure 2B). Six chil-
dren had IFN-γ producing Th1 cells against at least one of
the peptide pools of HPV16 E2, E6 and E7. The mother
of the child ID6B, who had the highest levels of IFN-γ,
TNF-α and IL-2, had cervical disease during the entire
FU, in which the disease varied from non-squamous
intraepithelial lesion (NSIL) to CIN3 with five different
HPV genotypes identified.
In 8 out of 10 mothers, T-cells had the capacity to
produce IL-2 against E2 protein and 6 of the 10 mothers
displayed an IL-2 response to E6. E7.2-induced IL-2
production by T-cells was detected in all three women.
HPV16-specific IL-2 responses were more frequently
found in children than in their mothers. The concentra-
tions of IL-2 were low, remaining mostly under 24.0 pg/mL
except in two children (IDs 6B and 10B). HPV16 in-
duced antigen-specific TNF-α secretion was detected in
six mothers and in five children (Figure 2B).
IL-10 and IL-17A were detected in all mothers and
children at least as a response to one of the HPV16 E2,
E6 or E7 peptides. They were usually detected in parallel,
the levels of IL-10 (up to 81.97 pg/mL) being usually
higher than those of IL-17A (up to 75.26 pg/mL) for the
individual peptide pools (Figure 3). The mother ID5A
with the highest IL-17A levels developed CIN3 and
tested HPV16 DNA-positive five times without any
HPV seropositive response during the FU. Her child had
a wider HPV16-specific T-cell proliferative response with
positive reaction to four different peptide pools (E2.1,
E2.2, E6.3 and E6.4). Interestingly, the highest level of
IL-10 was detected in child ID7B, whose mother (ID7A)
showed almost an identical history of cervical disease
(repeatedly HPV16 DNA-positive and CIN3), similar as
mother ID5A described above. However, ID7A was
HPV16-seropositive and had also a broader proliferative
response against HPV16 than most of other mothers in
our study.
Among control group of mothers, the highest cytokine
levels were with IFN-γ, IL-17 and IL-10 followed by IL-2,
IL-5 and TNF-α. The levels of all cytokines are presented
in the legend of the Figure 3. In the control group, the
secretion of TNF-α is the most minor comparing to the
other cytokines measured (data not shown). In study
group, the TNF-α have the fourth highest secreted
levels measured, instead.
To summarize, PBMC cultures displaying HPV16-
specific proliferative responses produced slightly higher
levels of inflammatory cytokines than PBMC cultures not
responding by proliferation. Especially Th1 –, Th2 –, and
Th17-type cytokines were identified in response to HPV16
peptides (Figure 2B). When comparing the mothers andchildren as groups the cytokine levels of IL-2 (p = 0.023),
and IL-5 (p = 0.028), were higher in children than their
mothers for all peptide pools, irrespective of the prolifera-
tive status, indicating that they have a more polarized
HPV16-specific Th1 and Th2 response. The children of
mothers having developed CIN3, showed significantly
higher IFN-γ (p = 0.032) and TNF-α (p = 0.008) levels than
the other children. In both those cytokine groups men-
tioned was one outliner, the child with ID6 (Figure 3). In
the pair-wise comparison of mother-child-pairs, the levels
of IL-2 and IL-5 showed statistically significant difference
between the mother and child (p = 0.013 and p = 0.009,
respectively).
HPV16 specific CD4 + CD25 + Foxp3+ regulatory T-cell
detection
The frequency of CD4 + CD25 + Foxp3+ cells after 7-day
stimulation was analyzed (Figure 2C). Two mothers had
positive responses at least to some peptide pools. Mother
ID2A showed positivity to peptide pool E2.2, while ID5A
showed responses to peptide pools E2.1, E2.2, E6.2, and
E7.1. Also in three children, Foxp3+ subsets were ex-
panded: ID6B responded to all pools except pool E2.1;
ID9B responded to pools E2.1 and E2.2, and ID10B pool
E2.2. Figure 2C represents the percentages of CD4 +
CD25 + Foxp3+ regulatory T-cells and CD4 + CD25 +
Foxp3 (negative) T-cells for all peptide pools. More
Foxp3+ responses were measured among control group
of mothers than study group of mothers but the levels
were lower. One mother showed no Foxp3+ responses
at all, but two other mothers showed responses at least to
five different peptide pools including all three peptides
(E2, E6 and E7). One mother showed Foxp3+ responses to
all HPV peptide pools (data not shown).
Discussion
In the present study, we examined the HPV16-specific
T-cell responses in 10 children born to mothers, who
had developed an incident CIN. According to the com-
mon dogma no HPV16 specific immune response should
be found as the offspring of the CIN mothers had not
started their sexual life yet. PBMCs derived from these
mother-child pairs were stimulated with HPV16 E2, E6,
and E7 peptides to estimate the lymphocyte proliferation
response and their cytokine secretion. Our results showed
that i) all these children harbored a T-cell response against
HPV16 peptides, ii) the responses of the children were
broader than those of their mothers (p = 0.0146).
In the present study, the children mounted concomitant
T-cell responses to HPV16 E2, E6 and/or E7. Previously
we reported that there are highly conserved domains in
HPV E2 protein sequence among different HPV geno-
types, which could lead to cross-reactivity between the E2
peptides of different types of HPV [13,14]. However,
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that the responses observed in these children most likely
reflect true circulating HPV16-specific memory T-cells
during their early childhood. The authors consider that ra-
ther perplexing, because all these children were sexually
inexperienced. These results indicate that these children
must have had an exposure to HPV16 infection at some
body sites. Given that the majority (6/10) of them had
detectable HPV DNA in their oral samples, oral mucosa
seems to be a plausible route of HPV acquisition and for
the stimulation of HPV16-specific adaptive immune re-
sponses. These results reinforce the concept that part of
HPV infections are acquired already at childhood by
non-sexual routes of transmission [21,22] and suggest
that HPV-immunity could be evoked early at life. Even
in the control group of the HPV-negative mothers an
HPV 16 specific immune response was found supporting
the view that nearly all women will be infected with HPV.
The important question is the age when one will get the
first exposure to HPV and how. The individual differences
between immune responses of HPV-infected persons will
determine either the virus infection will persist or will be
resolve such as our results of control groups showed.
More studies are needed to discover the crucial differences
in the immune systems concerning HPV infections.
Interestingly, rarely an HPV16 E6-specific and no
HPV16 E7-specific proliferative T-cell responses were
found in the mothers, despite the facts that all had de-
veloped an incident CIN as a consequence of a persist-
ent genital HPV16 infection and that the HPV16 E6 and
E7 proteins should be expressed in all HPV16–induced
CIN3 and CC lesions [41]. Five children displayed T-cell
reactivity to E2 and E6, two of whom also reacted to E7.
One other child reacted to HPV16 E2 and E7. The chil-
dren’s response pattern fits with previous data showing
that whereas E2- and E6-specific responses are readily
found in healthy individuals, this is not the case for E7
[13,37]. The absence of responses in their mothers also is
in line with previous data showing lack of responsiveness
in patients with CIN and CC [38].
The children’s oral sample tested HPV16-positive in
two cases, one was HPV18 positive and one HPV6 posi-
tive while two were HPV DNA-negative. Thus, there was
no straightforward correlation between the detection of
HPV in the children and their HPV-specific immune re-
sponse, except for the fact that five of the mothers of these
six children tested HPV16 and one HPV18 DNA-positive
in their cervical samples, and four were seropositive for
HPV16 or multiple types.
T helper type 1 cytokine IFN-γ and T helper type 2
cytokine IL-5 production is the characteristic for HPV16-
specific immune response among healthy subjects but this
is lost in patients with CC [37]. In the present study, the
cytokine levels of IL-2, IL-5, IL-10, and IL-17A werehigher in children than their mothers indicating that they
have a more polarized HPV16-specific Th1 and Th2 re-
sponse and this would be in line with their disease status.
Interestingly, mother’s high-grade CIN3 resulted in the
strongest and broadest HPV16-specific CMI response in
their children. A worth noticing is that there was one out-
liner among samples from children of mothers with CIN3,
which raised the total level of IFN-γ and TNF-α of those
children. Nevertheless, the produced IFN-γ and TNF-α
levels were still highest among children of mothers with
CIN3 than other children. The one child which has the
highest IFN-γ and TNF-α levels, had also highest IL2 and
IL-10 levels, so it might be that this child has fairly high
HPV-specific immune responses in its entirety.
Many studies have described HPV16–specific CMI re-
activity among women with HPV-induced CC or CIN
[36-38]. In the present study, all these women had devel-
oped incident CIN which was adequately treated, and who
consequently could be considered to have passed their
HPV-induced disease. However, they cannot be regarded
as healthy because of their long-lasting HPV history and
increased risk for recurrent disease. In a previous study,
increased CD4 + CD25+ Foxp3+ frequency was found in
women who developed CIN3 [42]. Thus, increased fre-
quencies of this cell types might predispose to increased
risk for high-grade CIN and CC. In the present cohort,
two mothers were positive for CD4 + CD25+ Foxp3+
cells, both of them having a persistent HPV16 infection
(a known risk factor for recurrent disease). In contrast
to all mothers, the children in this study should be con-
sidered as healthy and sexually inexperienced subjects.
However, three children were already CD4 + CD25 +
Foxp3-positive which might indicate that they are at
risk for HPV-associated diseases in the future.Conclusions
To conclude, our data support the view that HPV infec-
tion can be transmitted by non-sexual routes. The overall
higher HPV16-specific responses of the children who have
not started their sexual life than that of their mothers with
CIN suggest that an early transmission may also lead to
protective immunity. The exact mechanism remains yet
unknown and further studies are urgently needed.
Additional file
Additional file 1: Table S1. Characteristics of the mothers with CIN and
their children. The table summarizes the mothers’ medical history of cervical
lesions, oral and genital HPV status and HPV-specific serology, as well as the
oral HPV DNA status and HPV serology of their children, followed since birth
until present. The red color represents HPV16 positive DNA sample, the
purple HPV16 seropositive sample, the light green color cervical disease
of grade LSIL/NCIN/ASCUS, the yellow color CIN2, the blue color represents
CIN3 and the light grey negative sample. A =mother, B = child, baseline =
time of the birth, 3d = age of 3 days, 1 mo = age of one month etc.
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